Amicogen (092040.KQ) Stock Price

Amicogen Price

KOSDAQ·CLOSED
915.00
​
Market closed

Revenue has compounded at 13.3% per year over the past 14 years to 41.98 B KRW. Earnings per share have grown at 23.2% per year over the last 10 years. Amicogen's net margin stands at -71.4%, down from 3.0% several years earlier. Amicogen currently offers a dividend yield of about 2.49%. The payout ratio is around 14% of earnings.

Amicogen stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amicogen business model & stock analysis

Amicogen Inc is a biotechnology company based in Jinju, South Korea, operating within the healthcare sector. The company went public on September 12, 2013, and is listed on the Korean stock market with the ticker 092040.KQ and ISIN KR7092040005. Amicogen focuses on the development and commercialization of enzyme products and functional food materials. Its product portfolio includes specialized enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP), and protein A chromatography resins. The company distributes its products domestically within South Korea and internationally to markets such as China, Japan, the United States, Germany, and Thailand. Amicogen's operations are centered around biotechnology research and development, with an emphasis on creating innovative solutions for the healthcare and functional food industries. The company's headquarters are located in Jinju, Gyeongsangnam-Do, South Korea. While specific details about its founding year, key personnel, or acquisition history are not provided, the company has established itself as a producer of enzyme-based products and functional food ingredients, serving both local and global clients. The firm's website, www.amicogen.com, provides further information on its offerings and business activities.

Frequently asked questions about Amicogen

5 analysts currently rate the Amicogen stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Amicogen share trades at 0.61 EUR (915.00 KRW).

The Amicogen share (092040.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (092040.KQ).

The revenue cannot currently be calculated for Amicogen.

The profit cannot currently be calculated for Amicogen.

The P/E ratio cannot be calculated for Amicogen at the moment.

The P/S cannot be calculated for Amicogen currently.

The Eulerpool Quality Score for Amicogen is 1/10.

The ISIN of Amicogen is KR7092040005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Amicogen is 092040.KQ. The ticker symbol is used to trade Amicogen shares on the stock exchange.

Fair ValueTerminal
841.80 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website amicogen.com
Country
South Korea
Currency
KRW
Initial public offering
Sep 12, 2013
ISIN
KR7092040005
Cusip
Y0R76Q105
Market capitalization
50.27 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.53
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-20.21 %
Dividend
Dividend yield
0.00 %
Payout Ratio
15.25 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
22.00 %
Last updated Oct 16, 2026, 11:20 AM

Amicogen Peer Group

Amicogen Ticker

KOSDAQ · 092040.KQ

Amicogen FIGI

092040:KS · BBG0053YPDK2092040:KQ · BBG0053YPDM0

All fundamentals and in-depth analysis of Amicogen

Our stock analysis for Amicogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amicogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.